TP53 and cancer: The oncogenic alterations of gene function, due to gene mutations (such as in TERT, TP53, and CTNNB1), epigenetic changes, or altered transcriptional regulation can lead to the tumorigenesis of liver cancer and therefore represent potential drug targets for cancer therapy.